

Embargoed for release: Tuesday, 26th May 2015 at 11:00 CET

Fulhold Pharma Plc
(“Fulhold Pharma” or the “Company” (GXG:FUL))

Fulhold Pharma Plc: Resignation of Director

Fulhold Pharma Plc (GXG London: FUL) announces that with effect from 16th of March 2015 Mr David Cosgrove resigned from the Board of Directors.

Certain allegations have been made against Belvedere Management Group (“Belvedere”), headed by Mr Cosgrove, which Belvedere strenuously denies. Mr Cosgrove wishes to concentrate on rebutting these allegations and, accordingly, tendered his resignation from the Company. The Board of Directors wishes to thank Mr Cosgrove for his contribution to the Company’s success.

The Directors of the Issuer accept responsibility for the contents of this announcement.

For further information please contact:

Fulhold Pharma Plc

David Squire, CEO & Chairman
Stephen Leivers, Scientific Technical Director
info@fulhold.com

Tel: +44 (0)20 7127 5089

GXG Markets

Alex Bengier, Operations Director
ahb@gxgmarkets.co.uk

Tel: +44 (0)20 7653 1935

Investor & Media Relations

Sandra Spencer
corpcom@fulhold.com

Tel: +44 (0) 20 7127 5089

Mob: +44 (0)7749 813 717

About Fulhold Pharma Plc:

Fulhold Pharma develops and commercialises the worldwide use of Carbohydrate Derived Fulvic Acid (CHD-FA) in Human and Animal Healthcare. CHD-FA is produced by a unique, patented process and is pure and safe. It is a broad-spectrum anti-microbial and has anti-viral, anti-bacterial, anti-fungal and anti-inflammatory properties. Fulhold Pharma aims to add and secure value for shareholders as it engages with projects at all stages of the pharmaceutical value chain in realising the potential of CHD-FA.

Comprehensive information on Fulhold Pharma and its operations, including all press releases, annual reports and interim reports are available from Fulhold Pharma’s website at www.fulholdpharma.com

Ends